NCT00346632View on ClinicalTrials.gov

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromesChronic Myelogenous Leukemia
Interventions
DRUG

KW-2449

Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).

Trial Locations (4)

10021

Weill Cornell/New York Presbyterian Hospital, New York

21287

Johns Hopkins Hospital, Baltimore

77030

M.D. Anderson Cancer Center, Houston

08540

Contact Kyowa, Princeton

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY

NCT00346632 - An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter